Motif Bio PLC (LON:MTFB) was down 87.3% during mid-day trading on Thursday . The stock traded as low as GBX 4.69 ($0.06) and last traded at GBX 5.07 ($0.07). Approximately 41,374,580 shares changed hands during mid-day trading, an increase of 10,236% from the average daily volume of 400,302 shares. The stock had previously closed at GBX 40 ($0.52).
A number of equities analysts have weighed in on MTFB shares. Peel Hunt reaffirmed a “buy” rating on shares of Motif Bio in a research report on Monday, January 7th. Northland Securities reiterated a “buy” rating on shares of Motif Bio in a report on Wednesday, October 31st.
TRADEMARK VIOLATION WARNING: “Motif Bio (MTFB) Trading Down 87.3%” was originally posted by BBNS and is owned by of BBNS. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://baseballnewssource.com/2019/02/14/motif-bio-mtfb-trading-down-87-3/3214803.html.
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
Featured Story: Certificate of Deposit (CD)
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.